Liu Xuening, Li Zijian
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Basic Res Cardiol. 2025 Feb;120(1):11-24. doi: 10.1007/s00395-024-01054-0. Epub 2024 May 9.
Cardiovascular disease is the main factor contributing to the global burden of diseases, and the cardiotoxicity caused by anticancer drugs is an essential component that cannot be ignored. With the development of anticancer drugs, the survival period of cancer patients is prolonged; however, the cardiotoxicity caused by anticancer drugs is becoming increasingly prominent. Currently, cardiovascular disease has emerged as the second leading cause of mortality among long-term cancer survivors. Anticancer drug-induced cardiotoxicity has become a frontier and hot topic. The discovery of epigenetics has given the possibility of environmental changes in gene expression, protein synthesis, and traits. It has been found that epigenetics plays a pivotal role in promoting cardiovascular diseases, such as heart failure, coronary heart disease, and hypertension. In recent years, increasing studies have underscored the crucial roles played by epigenetics in anticancer drug-induced cardiotoxicity. Here, we provide a comprehensive overview of the role and mechanisms of epigenetics in anticancer drug-induced cardiotoxicity.
心血管疾病是导致全球疾病负担的主要因素，而抗癌药物引起的心脏毒性是不容忽视的重要组成部分。随着抗癌药物的发展，癌症患者的生存期得以延长；然而，抗癌药物引起的心脏毒性日益突出。目前，心血管疾病已成为长期癌症幸存者的第二大死亡原因。抗癌药物诱导的心脏毒性已成为一个前沿和热点话题。表观遗传学的发现为基因表达、蛋白质合成和性状的环境变化提供了可能性。研究发现，表观遗传学在促进心血管疾病（如心力衰竭、冠心病和高血压）方面起着关键作用。近年来，越来越多的研究强调了表观遗传学在抗癌药物诱导的心脏毒性中所起的关键作用。在此，我们全面概述了表观遗传学在抗癌药物诱导的心脏毒性中的作用及机制。
